AXL and Burkitt lymphoma: Thus, AXL inhibition by BGB324 in combination with gemcitabine can pharmacologically disrupt ROBO3-driven BL subtype aggressiveness and favor acquisition of a CLA-like chemosensitive phenotype in PDAC (Figure 7M).